ANGPTL4 stabilizes atherosclerotic plaques and modulates the phenotypic transition of vascular smooth muscle cells through KLF4 downregulation
1
조회
0
다운로드
1
인용
0
참고문헌
초록
Atherosclerosis, the leading cause of death, is a vascular disease of chronic inflammation. We recently showed that angiopoietin-like 4 (ANGPTL4) promotes cardiac repair by suppressing pathological inflammation. Given the fundamental contribution of inflammation to atherosclerosis, we assessed the role of ANGPTL4 in the development of atherosclerosis and determined whether ANGPTL4 regulates atherosclerotic plaque stability. We injected ANGPTL4 protein twice a week into atherosclerotic Apoe−/− mice and analyzed the atherosclerotic lesion size, inflammation, and plaque stability. In atherosclerotic mice, ANGPTL4 reduced atherosclerotic plaque size and vascular inflammation. In the atherosclerotic lesions and fibrous caps, the number of α-SMA(+), SM22α(+), and SM-MHC(+) cells was higher, while the number of CD68(+) and Mac2(+) cells was lower in the ANGPTL4 group. Most importantly, the fibrous cap was significantly thicker in the ANGPTL4 group than in the control group. Smooth muscle cells (SMCs) isolated from atherosclerotic aortas showed significantly increased expression of CD68 and Krüppel-like factor 4 (KLF4), a modulator of the vascular SMC phenotype, along with downregulation of α-SMA, and these changes were attenuated by ANGPTL4 treatment. Furthermore, ANGPTL4 reduced TNFα-induced NADPH oxidase 1 (NOX1), a major source of reactive oxygen species, resulting in the attenuation of KLF4-mediated SMC phenotypic changes. We showed that acute myocardial infarction (AMI) patients with higher levels of ANGPTL4 had fewer vascular events than AMI patients with lower levels of ANGPTL4 (p < 0.05). Our results reveal that ANGPTL4 treatment inhibits atherogenesis and suggest that targeting vascular stability and inflammation may serve as a novel therapeutic strategy to prevent and treat atherosclerosis. Even more importantly, ANGPTL4 treatment inhibited the phenotypic changes of SMCs into macrophage-like cells by downregulating NOX1 activation of KLF4, leading to the formation of more stable plaques.
Abstract
Atherosclerosis, the leading cause of death, is a vascular disease of chronic inflammation. We recently showed that angiopoietin-like 4 (ANGPTL4) promotes cardiac repair by suppressing pathological inflammation. Given the fundamental contribution of inflammation to atherosclerosis, we assessed the role of ANGPTL4 in the development of atherosclerosis and determined whether ANGPTL4 regulates atherosclerotic plaque stability. We injected ANGPTL4 protein twice a week into atherosclerotic Apoe−/− mice and analyzed the atherosclerotic lesion size, inflammation, and plaque stability. In atherosclerotic mice, ANGPTL4 reduced atherosclerotic plaque size and vascular inflammation. In the atherosclerotic lesions and fibrous caps, the number of α-SMA(+), SM22α(+), and SM-MHC(+) cells was higher, while the number of CD68(+) and Mac2(+) cells was lower in the ANGPTL4 group. Most importantly, the fibrous cap was significantly thicker in the ANGPTL4 group than in the control group. Smooth muscle cells (SMCs) isolated from atherosclerotic aortas showed significantly increased expression of CD68 and Krüppel-like factor 4 (KLF4), a modulator of the vascular SMC phenotype, along with downregulation of α-SMA, and these changes were attenuated by ANGPTL4 treatment. Furthermore, ANGPTL4 reduced TNFα-induced NADPH oxidase 1 (NOX1), a major source of reactive oxygen species, resulting in the attenuation of KLF4-mediated SMC phenotypic changes. We showed that acute myocardial infarction (AMI) patients with higher levels of ANGPTL4 had fewer vascular events than AMI patients with lower levels of ANGPTL4 (p < 0.05). Our results reveal that ANGPTL4 treatment inhibits atherogenesis and suggest that targeting vascular stability and inflammation may serve as a novel therapeutic strategy to prevent and treat atherosclerosis. Even more importantly, ANGPTL4 treatment inhibited the phenotypic changes of SMCs into macrophage-like cells by downregulating NOX1 activation of KLF4, leading to the formation of more stable plaques.
참고문헌 (56)
- Muller, J. E., "Circadian variation and triggers of onset of acute cardiovascular disease", Circulation, 79, pp.733~743 (1989)
- Arbab-Zadeh, A., "From detecting the vulnerable plaque to managing the vulnerable patient : JACC state-of-the-art review", J. Am. Coll. Cardiol, 74, pp.1582~1593 (2019)
- Bentzon, J. F., "Mechanisms of plaque formation and rupture", Circ. Res, 114, pp.1852~1866 (2014)
- Karthikeyan, V. J., "Statins and intra-plaque angiogenesis in carotid artery disease", Atherosclerosis, 192, pp.455~456 (2007)
- Nie, P., "Atorvastatin improves plaque stability in ApoE-knockout mice by regulating chemokines and chemokine receptors", PLoS ONE, 9, pp.e97009~ (2014)
- Hafiane, A., "Vulnerable plaque, characteristics, detection, and potential therapies", J. Cardiovasc. Dev. Dis, 6, pp.26~ (2019)
- Nissen, S. E., "Effect of very high-intensity statin therapy on regression of coronary atherosclerosis : the ASTEROID trial", JAMA, 295, pp.1556~1565 (2006)
- Nicholls, S. J., "Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis", JAMA, 297, pp.499~508 (2007)
- Puri, R., "Non-HDL cholesterol and triglycerides : implications for coronary atheroma progression and clinical events", Arterioscler. Thromb. Vasc. Biol, 36, pp.2220~2228 (2016)
- Tang, X., "The effect of statin therapy on plaque regression following acute coronary syndrome : a meta-analysis of prospective trials", Coron. Artery Dis, 27, pp.636~649 (2016)
- Puri, R., "Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition : insights from SATURN", Eur. Heart J. Cardiovasc. Imaging, 15, pp.380~388 (2014)
- Bayturan, O., "Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol", J. Am. Coll. Cardiol, 55, pp.2736~2742 (2010)
- Ridker, P. M., "Antiinflammatory therapy with canakinumab for atherosclerotic disease", N. Engl. J. Med, 377, pp.1119~1131 (2017)
- Ridker, P. M., "Low-dose methotrexate for the prevention of atherosclerotic events", N. Engl. J. Med, 380, pp.752~762 (2019)
- Tardif, J. C., "Efficacy and safety of low-dose colchicine after myocardial infarction", N. Engl. J. Med, 381, pp.2497~2505 (2019)
- Cho, D. I., "Antiinflammatory activity of ANGPTL4 facilitates macrophage polarization to induce cardiac repair", JCI Insight, 4, pp.e125437~ (2019)
- Bennett, M. R., "Vascular smooth muscle cells in atherosclerosis", Circ. Res, 118, pp.692~702 (2016)
- Shankman, L. S., "KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis", Nat. Med, 21, pp.628~637 (2015)
- Doran, A. C., "Role of smooth muscle cells in the initiation and early progression of atherosclerosis", Arterioscler. Thromb. Vasc. Biol, 28, pp.812~819 (2008)
- Ross, R., "The pathogenesis of atherosclerosis : a perspective for the 1990s", Nature, 362, pp.801~809 (1993)
- Owens, G. K., "Molecular regulation of vascular smooth muscle cell differentiation in development and disease", Physiol. Rev, 84, pp.767~801 (2004)
- Alencar, G. F., "Stem cell pluripotency genes Klf4 and Oct4 regulate complex SMC phenotypic changes critical in late-stage atherosclerotic lesion pathogenesis", Circulation, 142, pp.2045~2059 (2020)
- Pan, H., "Single-cell genomics reveals a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human", Circulation, 142, pp.2060~2075 (2020)
- Mulvihill, E. R., "Atherosclerotic plaque smooth muscle cells have a distinct phenotype", Arterioscler. Thromb. Vasc. Biol, 24, pp.1283~1289 (2004)
- Nadkarni, S. K., "Evaluation of collagen in atherosclerotic plaques: the use of two coherent laser-based imaging methods", Lasers Med. Sci, 24, pp.439~445 (2009)
- Davies, M. J., "Risk of thrombosis in human atherosclerotic plaques : role of extracellular lipid, macrophage, and smooth muscle cell content", Br. Heart J, 69, pp.377~381 (1993)
- Vendrov, A. E., "NOXA1-dependent NADPH oxidase regulates redox signaling and phenotype of vascular smooth muscle cell during atherogenesis", Redox Biol, 21, pp.101063~ (2019)
- Stitziel, N. O., "Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease", N. Engl. J. Med, 374, pp.1134~1144 (2016)
- Dewey, F. E., "Inactivating variants in ANGPTL4 and risk of coronary artery disease", N. Engl. J. Med, 374, pp.1123~1133 (2016)
- Aryal, B., "ANGPTL4 in metabolic and cardiovascular disease", Trends Mol. Med, 25, pp.723~734 (2019)
- Hato, T., "The role of angiopoietin-like proteins in angiogenesis and metabolism", Trends Cardiovasc. Med, 18, pp.6~14 (2008)
- Santulli, G., "Angiopoietin-like proteins : a comprehensive look", Front. Endocrinol, 5, pp.4~ (2014)
- Koishi, R., "Angptl3 regulates lipid metabolism in mice", Nat. Genet, 30, pp.151~157 (2002)
- Shimizugawa, T., "ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase", J. Biol. Chem, 277, pp.33742~33748 (2002)
- Georgiadi, A., "Overexpression of angiopoietin-like protein 4 protects against atherosclerosis development", Arterioscler. Thromb. Vasc. Biol, 33, pp.1529~1537 (2013)
- Aryal, B., "ANGPTL4 deficiency in haematopoietic cells promotes monocyte expansion and atherosclerosis progression", Nat. Commun, 7, pp.12313~ (2016)
- Dai, X., "SM22alpha suppresses cytokine-induced inflammation and the transcription of NF-kappaB inducing kinase(Nik)by modulating SRF transcriptional activity in vascular smooth muscle cells", PLoS ONE, 12, pp.e0190191~ (2017)
- Chappell, J., "Extensive proliferation of a subset of differentiated, yet plastic, medial vascular smooth muscle cells contributes to neointimal formation in mouse injury and atherosclerosis models", Circ. Res, 119, pp.1313~1323 (2016)
- Feil, S., "Transdifferentiation of vascular smooth muscle cells to macrophagelike cells during atherogenesis", Circ. Res, 115, pp.662~667 (2014)
- Szöcs, K., "Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury", Arterioscler. Thromb. Vasc. Biol, 22, pp.21~27 (2002)
- Xu, S., "Increased expression of Nox1 in neointimal smooth muscle cells promotes activation of matrix metalloproteinase-9", J. Vasc. Res, 49, pp.242~248 (2012)
- Shen, C. -J., "Oleic acid-induced NOX4 is dependent on ANGPTL4 expression to promote human colorectal cancer metastasis", Theranostics, 10, pp.7083~ (2020)
- Yang, W. -H., "A TAZ–ANGPTL4–NOX2 axis regulates ferroptotic cell death and chemoresistance in epithelial ovarian cancerTAZ promotes ferroptosis in OvCa", Mol. Cancer Res, 18, pp.79~90 (2020)
- Zhu, P., "Angiopoietin-like 4 protein elevates the prosurvival intracellular O2- : H2O2 ratio and confers anoikis resistance to tumors", Cancer Cell, 19, pp.401~415 (2011)
- Harpaz, D., "Family history of coronary artery disease and prognosis after first acute myocardial infarction in a national survey", Cardiology, 102, pp.140~146 (2004)
- Ridker, P. M., "Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men", N. Engl. J. Med, 336, pp.973~979 (1997)
- Ridker, P. M., "C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women", N. Engl. J. Med, 342, pp.836~843 (2000)
- Bouleti, C., "Angiopoietin-like 4 serum levels on admission for acute myocardial infarction are associated with no-reflow", Int. J. Cardiol, 187, pp.511~516 (2015)
- Smart-Halajko, M. C., "The relationship between plasma angiopoietin-like protein 4 levels, angiopoietin-like protein 4 genotype, and coronary heart disease risk", Arterioscler. Thromb. Vasc. Biol, 30, pp.2277~2282 (2010)
- Gusarova, V., "Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes", Nat. Commun, 9, pp.2252~ (2018)
- Giugliano, G. R., "Meta-analysis of corticosteroid treatment in acute myocardial infarction", Am. J. Cardiol, 91, pp.1055~1059 (2003)
- Schjerning Olsen, A. M., "Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction", JAMA, 313, pp.805~814 (2015)
- Padfield, G. J., "Cardiovascular effects of tumour necrosis factor alpha antagonism in patients with acute myocardial infarction : a first in human study", Heart, 99, pp.1330~1335 (2013)
- Mann, D. L., "Targeted anticytokine therapy in patients with chronic heart failure : results of the Randomized Etanercept Worldwide Evaluation(RENEWAL)", Circulation, 109, pp.1594~1602 (2004)
- Morton, A. C., "The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes : the MRC-ILA Heart Study", Eur. Heart J, 36, pp.377~384 (2015)
- Gomez, D., "Interleukin-1beta has atheroprotective effects in advanced atherosclerotic lesions of mice", Nat. Med, 24, pp.1418~1429 (2018)